Broadwing Bio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$9.9M
- Investors
-
3
Broadwing Bio General Information
Description
Operator of a biotechnology company intended to develop targeted antibody therapies for the treatment of ophthalmic diseases. The company's operations mainly involve conducting programs directed to genetically validated ophthalmology targets using antibody discovery technologies, enabling patients to receive effective eye treatment.
Contact Information
Website
www.broadwing.bioCorporate Office
- 171 Oyster Point Boulevard
- Suite 300
- San Francisco, CA 94080
- United States
Corporate Office
- 171 Oyster Point Boulevard
- Suite 300
- San Francisco, CA 94080
- United States
Broadwing Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 02-Feb-2024 | $9.9M | Completed | Pre-Clinical Trials | ||
| 1. Joint Venture | 07-Dec-2020 | Completed | Pre-Clinical Trials |
Broadwing Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 16,100,806 | $0.000001 | $0.29 | $0.29 | 1x | $0.29 | 31.19% |
Broadwing Bio Patents
Broadwing Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024227154-A1 | Complement component 3 (c3)-specific antibodies and uses thereof | Inactive | 28-Apr-2023 | ||
| AU-2023259251-A1 | Angiopoietin-related protein 7-specific antibodies and uses thereof | Pending | 29-Apr-2022 | ||
| EP-4514470-A1 | Angiopoietin-related protein 7-specific antibodies and uses thereof | Pending | 29-Apr-2022 | ||
| US-20250296996-A1 | Angiopoietin-related protein 7-specific antibodies and uses thereof | Pending | 29-Apr-2022 | ||
| WO-2023212294-A1 | Angiopoietin-related protein 7-specific antibodies and uses thereof | Inactive | 29-Apr-2022 | C07K16/22 |
Broadwing Bio Signals
Broadwing Bio Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Echo Investment Capital | PE/Buyout | Minority | ||
| Alloy Therapeutics | VC-Backed Company | Majority | ||
| Maze Therapeutics | Corporation | Majority |
Broadwing Bio FAQs
-
When was Broadwing Bio founded?
Broadwing Bio was founded in 2020.
-
Where is Broadwing Bio headquartered?
Broadwing Bio is headquartered in San Francisco, CA.
-
What is the size of Broadwing Bio?
Broadwing Bio has 3 total employees.
-
What industry is Broadwing Bio in?
Broadwing Bio’s primary industry is Biotechnology.
-
Is Broadwing Bio a private or public company?
Broadwing Bio is a Private company.
-
What is the current valuation of Broadwing Bio?
The current valuation of Broadwing Bio is .
-
What is Broadwing Bio’s current revenue?
The current revenue for Broadwing Bio is .
-
How much funding has Broadwing Bio raised over time?
Broadwing Bio has raised $9.9M.
-
Who are Broadwing Bio’s investors?
Echo Investment Capital, Alloy Therapeutics, and Maze Therapeutics have invested in Broadwing Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process